{ "schemaVersion": 2, "eyebrow": "Psychiatry", "title": "Social Anxiety Disorder", "summary": "Diagnose social anxiety disorder by persistent fear of negative evaluation, avoidance, disproportionate anxiety, and functional impairment; screen with Mini-SPIN or quantify severity with SPIN or LSAS. Select disorder-specific CBT first when acceptable, and use an SSRI when pharmacotherapy is preferred or needed.", "seoDescription": "Clinical diagnosis and treatment of social anxiety disorder: screening, comorbidity assessment, CBT selection, SSRI use, and follow-up.", "clinicalQuestion": "How should clinicians identify, assess, and treat social anxiety disorder in adults and young people?", "specialty": "Psychiatry", "audience": "U.S. physicians and medical trainees", "tags": [ "social anxiety disorder", "social phobia", "Mini-SPIN", "SPIN", "Liebowitz Social Anxiety Scale", "cognitive behavioral therapy", "sertraline" ], "keyTakeaways": [ "Establish that feared social or performance situations provoke anxiety related to scrutiny or embarrassment, lead to avoidance or endurance with marked distress, and cause functional impairment before assigning social anxiety disorder. [1][18]", "Use the 3-item Mini-SPIN for identification; use a validated measure such as SPIN or LSAS to quantify baseline severity and track response. [22]", "Offer disorder-specific CBT delivered by a competent practitioner; CBT has broad evidence of efficacy for social anxiety disorder and is superior to wait-list control in randomized psychotherapy trials. [6][7][21]", "Sertraline has FDA-label evidence for adult social anxiety disorder from two placebo-controlled trials using LSAS and CGI-I response outcomes. [1]", "Assess suicide risk, depression, other anxiety disorders, alcohol or drug misuse, and nicotine dependence because psychiatric comorbidity is common and changes parallel treatment needs. [18][19][22]" ], "sections": [ { "id": "confirm-the-diagnosis", "eyebrow": "Assessment", "heading": "Confirm clinically significant social anxiety and measure severity", "intro": "Separate pervasive fear of negative evaluation from ordinary shyness, isolated performance anxiety, and another primary psychiatric disorder.", "paragraphs": [ "Document the feared situations, anticipated consequence, anxiety response, avoidance pattern, and functional cost. Social anxiety disorder is characterized by marked, persistent fear of social or performance situations involving unfamiliar people or possible scrutiny, with concern about humiliation or embarrassment; exposure almost always provokes anxiety, and patients avoid situations or endure them with intense distress. The fear and anticipatory avoidance must be associated with marked distress or impairment. [1][18]", "For efficient case finding, use the 3-item Mini-Social Phobia Inventory (Mini-SPIN). If screening is positive or the history remains suggestive, obtain a structured description of current social anxiety, avoidance, associated problems, and circumstances, then record baseline severity with the Social Phobia Inventory (SPIN) or Liebowitz Social Anxiety Scale (LSAS). Repeat the same instrument during treatment rather than relying solely on a global impression of improvement. [22]", "Map the feared situations before treatment selection. A circumscribed performance presentation may center on speaking, eating, drinking, or writing while observed, whereas generalized social anxiety involves multiple interactions such as meeting unfamiliar people, speaking with authority figures, and public activities. This map becomes the exposure hierarchy and identifies occupational, academic, and interpersonal targets for outcome monitoring. [17]" ], "bullets": [ "Record avoided situations and safety behaviors that maintain avoidance; use these as explicit behavioral treatment targets. [1][23]", "Assess educational, occupational, social, and quality-of-life effects, because guideline outcomes include symptoms as well as functional recovery. [19]", "In adolescents, obtain developmentally appropriate information about peer situations, school participation, and family context before choosing individual, group, or digital CBT delivery. [9][23][24]" ], "subsections": [], "table": { "caption": "Practical assessment framework for suspected social anxiety disorder. [1][18][22]", "columns": [ "Clinical domain", "Finding supporting social anxiety disorder", "Immediate next action" ], "rows": [ [ "Core fear", "Fear of scrutiny, humiliation, or embarrassment in social or performance situations. [1][18]", "Elicit the feared prediction and the situations that trigger it. [1][23]" ], [ "Behavioral pattern", "Avoidance, or endurance with intense anxiety or distress. [1][18]", "List avoided activities and rank them for graduated exposure. [19][23]" ], [ "Clinical significance", "Marked distress or impairment attributable to fear and avoidance. [1]", "Document work, school, relationship, and participation consequences. [19]" ], [ "Measurement", "Positive Mini-SPIN identifies need for fuller assessment; SPIN or LSAS quantifies severity. [22]", "Record a baseline SPIN or LSAS and use the same scale to monitor treatment. [22]" ] ] } }, { "id": "risk-and-comorbidity", "eyebrow": "Safety", "heading": "Identify comorbidity, substance-related avoidance, and suicide risk before treatment", "intro": "Social anxiety disorder often coexists with conditions that require concurrent management rather than diagnostic exclusion.", "paragraphs": [ "Perform a psychiatric comorbidity assessment rather than treating social avoidance as a stand-alone complaint. Among adults with a primary social anxiety disorder diagnosis, approximately four-fifths experience at least one other psychiatric disorder during life; co-occurring anxiety disorders are reported in up to 70%, affective disorders in up to 65%, nicotine dependence in 27%, and substance-use disorder in about 20%. [18]", "Ask whether alcohol, sedatives, cannabis, stimulants, or other drugs are being used before social exposure, after events, or to manage anticipatory anxiety. Substance misuse does not preclude treatment for social anxiety disorder. For hazardous alcohol or drug misuse, provide a brief intervention; for harmful or dependent use, consider referral to a specialist alcohol or drug service while maintaining treatment for social anxiety disorder. [19][22]", "Assess suicidal ideation, intent, plan, means, protective factors, and acute changes in risk at evaluation and when initiating treatment. For patients assessed as at risk of suicide, arrange weekly review until increased risk resolves; then review every 2 to 4 weeks during the first 3 months of treatment and monthly thereafter, while continuing support for graduated exposure to feared situations. [19]" ], "bullets": [ "When depression is present, measure and treat it concurrently; depression did not worsen CBT outcome for panic and agoraphobia in a multicenter trial, but social anxiety disorder-specific outcome assessment should still remain explicit. [6]", "Determine whether substance use is principally a consequence of social anxiety, because this informs sequencing of the brief intervention, addiction referral, and exposure-based treatment. [19]", "Do not abandon exposure goals because of suicide-risk monitoring; use closer contact and a graded plan rather than unsupported reassurance. [19]" ], "subsections": [], "table": { "caption": "Comorbidity actions that alter the initial management plan. [18][19][22]", "columns": [ "Finding", "Clinical implication", "Action" ], "rows": [ [ "Another anxiety disorder or affective disorder", "Psychiatric comorbidity is frequent in social anxiety disorder. [18]", "Define each active syndrome and track social anxiety with SPIN or LSAS alongside the comorbid condition. [22]" ], [ "Hazardous alcohol or drug use", "May function as avoidance or self-medication and should not preclude social anxiety treatment. [19]", "Provide a brief alcohol or drug intervention and continue social anxiety treatment. [19][22]" ], [ "Harmful or dependent alcohol or drug use", "Requires addiction-focused care in parallel with anxiety treatment. [19][22]", "Consider referral to a specialist alcohol or drug misuse service. [19][22]" ], [ "Suicide risk", "Requires intensified early follow-up. [19]", "Review weekly until increased risk resolves, then every 2 to 4 weeks during the first 3 months and monthly thereafter. [19]" ] ] } }, { "id": "psychotherapy-first-line", "eyebrow": "Definitive treatment", "heading": "Use disorder-specific CBT to reverse avoidance", "intro": "Match psychotherapy to the patient’s feared situations and maintain exposure work as the behavioral endpoint.", "paragraphs": [ "Offer CBT from a competent practitioner using a relevant treatment manual. CBT is supported across anxiety disorders, including social anxiety disorder, and in a multicenter randomized trial both CBT and psychodynamic therapy produced significantly higher response and remission than waiting-list control among adults with social anxiety disorder. [6][7][21][22]", "For social anxiety disorder, structure CBT around a patient-specific formulation: feared negative evaluation, self-focused attention, maladaptive interpretations, safety behaviors, and avoidance. Use behavioral experiments and graduated exposure to test feared predictions in the situations identified at intake. Cognitive approaches derived from the Clark and Wells model specifically target processes maintaining social anxiety, and adolescent adaptations should address developmental peer and school contexts. [23]", "Group CBT can be appropriate when the treatment plan includes social-skills work, assertiveness, cognitive restructuring, problem-solving, and exposure. Adolescent group CBT formats have reduced social anxiety versus control conditions; choose group treatment only if the patient can engage with the exposure demands rather than using the group setting as a lower-intensity substitute for behavioral change. [9]" ], "bullets": [ "Use the baseline SPIN or LSAS to define measurable targets and repeat it to assess response. [22]", "Continue graduated exposure even when suicide-risk surveillance is required, with a pace matched to clinical stability. [19]", "Digital CBT may improve access, but outcome evidence in youth is heterogeneous: in one guided online adolescent trial, social anxiety did not improve significantly immediately after treatment, although findings suggested possible value for indicated prevention. [10]" ], "subsections": [ { "heading": "When to consider psychodynamic therapy", "paragraphs": [ "Manual-guided psychodynamic therapy is an evidence-based psychotherapy option when disorder-specific CBT is unavailable, unacceptable, or unsuccessful. In the SOPHO-NET multicenter trial, both psychodynamic therapy and CBT were superior to waiting-list control for LSAS-rated response and remission; the cited result does not establish equivalence between the two active treatments. [7]" ], "bullets": [] } ], "table": { "caption": "Psychotherapy selection for social anxiety disorder. [6][7][9][10][21][23]", "columns": [ "Option", "Use case", "Essential treatment target" ], "rows": [ [ "Individual disorder-specific CBT", "Preferred when exposure can be individualized to the patient’s avoided social and performance situations. [6][21][23]", "Behavioral experiments, graduated exposure, and reduction of safety behaviors. [23]" ], [ "Group CBT", "Appropriate when structured social-skills, cognitive, and exposure work fits the patient’s goals. [9]", "Assertiveness, problem-solving, cognitive restructuring, and exposure. [9]" ], [ "Psychodynamic therapy", "Consider when CBT is unavailable, declined, or has not achieved adequate response. [7]", "Manual-guided psychotherapy with response and remission monitoring. [7]" ], [ "Guided digital intervention", "Consider as an access-oriented adjunct or low-threshold option, particularly for indicated prevention in youth. [10]", "Monitor symptoms rather than presuming post-treatment benefit. [10]" ] ] } }, { "id": "medication-and-follow-up", "eyebrow": "Pharmacotherapy", "heading": "Use SSRI treatment when medication is selected and monitor with functional targets", "intro": "Choose medication when the patient prefers pharmacotherapy, cannot access adequate CBT, or requires a combined strategy after shared decision-making.", "paragraphs": [ "Sertraline is FDA-labeled for adult social anxiety disorder. Its efficacy was established in two placebo-controlled adult outpatient trials enrolling patients with DSM-IV social anxiety disorder; primary outcomes included LSAS change and CGI-I response, defined as CGI-I score 1 or 2. Use a consistent baseline symptom measure and functional target so that continuation reflects observable benefit rather than medication exposure alone. [1]", "Do not infer pediatric medication efficacy from adult sertraline labeling. A trial history cited for children and adolescents includes fluvoxamine in patients aged 6 to 17 years with social phobia, social anxiety disorder, or generalized anxiety disorder, but this excerpt does not provide a pediatric dosing or treatment algorithm. Prioritize developmentally adapted CBT and use specialist-informed medication decisions when pharmacotherapy is being considered for youth. [16][24]", "At follow-up, reassess avoidance, social participation, school or work functioning, SPIN or LSAS score, adverse effects, adherence, substance use, and suicide risk. A patient reporting reduced distress but still avoiding the core feared situation has not completed the behavioral target; revise the exposure hierarchy, evaluate psychotherapy engagement, and address comorbid depression or substance use rather than labeling treatment success prematurely. [19][22][23]" ], "bullets": [ "Use LSAS or SPIN serially; LSAS and CGI-I were the outcome measures in adult sertraline studies. [1][22]", "For patients with active suicide risk, follow weekly until risk is no longer elevated, then every 2 to 4 weeks during the first 3 months and monthly thereafter. [19]", "Keep substance-use treatment and social anxiety treatment active in parallel when alcohol or drug use is hazardous, harmful, or dependent. [19][22]" ], "subsections": [], "table": { "caption": "Medication and monitoring decisions for social anxiety disorder. [1][16][19][22]", "columns": [ "Decision point", "Action", "How to monitor" ], "rows": [ [ "Adult selects pharmacotherapy", "Consider sertraline, which is FDA-labeled for adult social anxiety disorder. [1]", "Track LSAS or SPIN, CGI-style global change, avoidance, and functional goals. [1][22]" ], [ "Adolescent requires treatment", "Prioritize developmentally adapted CBT; seek specialist-informed medication planning if pharmacotherapy is under consideration. [23][24]", "Track school, peer, and family-relevant functioning with symptom severity. [9][23]" ], [ "Hazardous substance use", "Provide a brief intervention without withholding social anxiety treatment. [19][22]", "Reassess use pattern and whether it is linked to anticipated or completed social exposure. [19]" ], [ "Elevated suicide risk", "Increase contact frequency while maintaining a graded exposure plan. [19]", "Weekly until increased risk resolves; then every 2 to 4 weeks for 3 months and monthly thereafter. [19]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "[PDF] Sertraline Hydrochloride Tablets USP - DailyMed", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=6b532e6a-b040-4a10-a242-fb6d8dfc0852&type=pdf", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov" }, { "number": 2, "title": "Generalized anxiety disorder - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/120?q=Generalised+anxiety+disorder&%3Bc=suggested", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 3, "title": "Frontiers and hotspots in anxiety disorders: A bibliometric analysis ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)11732-X", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 4, "title": "Prevention and treatment of social anxiety disorder in adolescents: mixed method randomised controlled trial of the guided online intervention SOPHIE | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-025-10193-w", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 5, "title": "Multi-session CBM-I for social anxiety: examining psychopathology, cognitive, neural, and psychophysiological effects in a randomized controlled trial | Translational Psychiatry", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41398-026-04122-2", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 6, "title": "Anxiety disorders | Nature Reviews Disease Primers", "detail": "www.nature.com", "url": "https://www.nature.com/articles/nrdp201724", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 7, "title": "The predictive value of cortisol in psychodynamic psychotherapy for social anxiety disorder: Extended results of the SOPHONET-Study | Translational Psychiatry", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41398-024-02882-3", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 8, "title": "A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S088761850000027X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 9, "title": "Psychological interventions for social anxiety disorder in children and adolescents: A systematic review and network meta-analysis", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165032724013156", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 10, "title": "Digital Mental Health Interventions for the Prevention and Treatment of Social Anxiety Disorder in Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis of Randomized Controlled Trials", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/org/science/article/pii/S1438887125008167", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 11, "title": "Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0887618507000205", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 12, "title": "Depressive and anxiety disorders linked to... : Medicine - Ovid", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/fulltext/2025/11140/depressive_and_anxiety_disorders_linked_to.140.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 13, "title": "Treatment of Anxiety Disorders - Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/book/61856/chapter/547117580", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 14, "title": "Fluvoxamine CR in the long-term treatment of social ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article-pdf/6/4/317/1994747/6-4-317.pdf", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 15, "title": "The evidence-based pharmacotherapy of social anxiety disorder", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/16/1/235/629354", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 16, "title": "10 Treatment of Anxiety Disorders - Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/book/38543/chapter/333672174", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 17, "title": "[PDF] Social anxiety disorder - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg159/documents/social-anxiety-disorder-final-scope2", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 18, "title": "SOCIAL ANXIETY DISORDER - Social Anxiety Disorder - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK327674", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Social anxiety disorder: recognition, assessment and ...", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/n/nicecg159guid/pdf", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 20, "title": "SCOPE FOR THE DEVELOPMENT OF THE CLINICAL GUIDELINE - Social Anxiety Disorder - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK327659", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 21, "title": "Clinical practice guideline for social anxiety disorder (2021) - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10496046", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 22, "title": "SUMMARY OF RECOMMENDATIONS - Social Anxiety Disorder - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK327653", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 23, "title": "Understanding Social Anxiety Disorder in Adolescents and Improving Treatment Outcomes: Applying the Cognitive Model of Clark and Wells (1995) - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6447508", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 24, "title": "A clinician's quick guide of evidence-based approaches: Childhood anxiety disorders", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4467238", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "[PDF] Sertraline Hydrochloride Tablets USP - DailyMed", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=6b532e6a-b040-4a10-a242-fb6d8dfc0852&type=pdf", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov", "snippet": "Study outcome was assessed by (a) the Liebowitz Social Anxiety Scale (LSAS), a 24-item clinician administered instrument that measures fear, anxiety and avoidance of social and performance situations, and by (b) the proportion of responders as defined by the Clinical Global Impression of Improvement", "score": 0.19664136 }, { "number": 2, "title": "Generalized anxiety disorder - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/120?q=Generalised+anxiety+disorder&%3Bc=suggested", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014 May;28(5):403-39.Ab", "score": 0.36006194 }, { "number": 3, "title": "Frontiers and hotspots in anxiety disorders: A bibliometric analysis ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)11732-X", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "Anxiety disorders are categorized as a cluster of mental conditions characterized by excessive fear, persistent anxiousness, specific phobia,", "score": 0.14512776 }, { "number": 4, "title": "Prevention and treatment of social anxiety disorder in adolescents: mixed method randomised controlled trial of the guided online intervention SOPHIE | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-025-10193-w", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nPubMed \nPubMed Central \nGoogle Scholar\n\nMcGorry, P. D. & Mei, C. Early intervention in youth mental health: progress and future directions. Evid. Based Ment Health. 21, 182–184 (2018).\n\nArticle \nPubMed \nPubMed Central \nGoogle Scholar\n\nEbert, D. D. et al. Internet and Computer-Based cognitiv", "score": 0.6932451 }, { "number": 5, "title": "Multi-session CBM-I for social anxiety: examining psychopathology, cognitive, neural, and psychophysiological effects in a randomized controlled trial | Translational Psychiatry", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41398-026-04122-2", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Fehm L, Beesdo K, Jacobi F, Fiedler A. Social anxiety disorder above and below the diagnostic threshold: prevalence, comorbidity and impairment in the general population. Soc Psychiat Epidemiol. 2008;43:257–65.\n\nArticle \nGoogle Scholar\n\nCarpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Ho", "score": 0.63723457 }, { "number": 6, "title": "Anxiety disorders | Nature Reviews Disease Primers", "detail": "www.nature.com", "url": "https://www.nature.com/articles/nrdp201724", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Google Scholar\n\nCuijpers, P., Cristea, I. A., Karyotaki, E., Reijnders, M. & Huibers, M. J. H. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry 15, 245–258 (2016). This meta-analysis presents a large b", "score": 0.6350646 }, { "number": 7, "title": "The predictive value of cortisol in psychodynamic psychotherapy for social anxiety disorder: Extended results of the SOPHONET-Study | Translational Psychiatry", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41398-024-02882-3", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Google Scholar\n\nSalzer S, Stefini A, Kronmüller KT, Leibing E, Leichsenring F, Henningsen P, et al. Cognitive-Behavioral and Psychodynamic Therapy in Adolescents with Social Anxiety Disorder: A Multicenter Randomized Controlled Trial. Psychother Psychosomatics. 2018;87:223–33.\n\nArticle \nGoogle Schol", "score": 0.60805947 }, { "number": 8, "title": "A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S088761850000027X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia - ScienceDirect\n# A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia. —There is a growing body of evidence tha", "score": 0.6191726 }, { "number": 9, "title": "Psychological interventions for social anxiety disorder in children and adolescents: A systematic review and network meta-analysis", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165032724013156", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "SET-C is largely used to inform the social skills and exposure sessions, while Ronald Rapee's (1998) book is used to inform the realistic thinking and relapse prevention sessions (Masia et al., 2001). Cognitive-Behavioural Group Therapy for Adolescents (CBGT-A) is a group cognitive behavioural thera", "score": 0.5611433 }, { "number": 10, "title": "Digital Mental Health Interventions for the Prevention and Treatment of Social Anxiety Disorder in Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis of Randomized Controlled Trials", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/org/science/article/pii/S1438887125008167", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Open access\n\n### Background\n\nSocial anxiety disorder (SAD) substantially affects young individuals’ social and academic functioning, emphasizing the need for accessible and effective treatments such as digital mental health interventions (DMHIs).\n\n### Objective\n\nThis systematic review and meta-analy", "score": 0.5585443 }, { "number": 11, "title": "Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0887618507000205", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "(2000) \n J.C. Ballenger _et al._\n### Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety\n\n### Journal of Clinical Psychiatry (1998) \n D.C. Beidel\n### Social anxiety disorder: etiology and early clinical presentation\n\n### Journal of Clin", "score": 0.42677602 }, { "number": 12, "title": "Depressive and anxiety disorders linked to... : Medicine - Ovid", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/fulltext/2025/11140/depressive_and_anxiety_disorders_linked_to.140.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Anxiety disorders included panic disorder, agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress", "score": 0.18042447 }, { "number": 13, "title": "Treatment of Anxiety Disorders - Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/book/61856/chapter/547117580", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "The manual-based CBT intervention (called Coping Cat) targets one or more of the following disorders: social anxiety disorder, social phobia,", "score": 0.5553635 }, { "number": 14, "title": "Fluvoxamine CR in the long-term treatment of social ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article-pdf/6/4/317/1994747/6-4-317.pdf", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by DJ Stein · 2003 · Cited by 76 — Fluvoxamine CR has been reported effective in the short-term (12-wk) treatment of generalized social anxiety disorder (social phobia).Read more", "score": 0.49670476 }, { "number": 15, "title": "The evidence-based pharmacotherapy of social anxiety disorder", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/16/1/235/629354", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "Abstract. Social anxiety disorder (SAD) is a highly prevalent and often disabling disorder. This paper reviews the pharmacological treatment of SAD based o.", "score": 0.40797067 }, { "number": 16, "title": "10 Treatment of Anxiety Disorders - Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/book/38543/chapter/333672174", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "In 2001, fluvoxamine, an SSRI, was studied in children and adolescents 6 to 17 years of age with either social phobia, SAD, or generalized anxiety disorder (GAD ...Read more", "score": 0.40014032 }, { "number": 17, "title": "[PDF] Social anxiety disorder - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg159/documents/social-anxiety-disorder-final-scope2", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "Social anxiety disorder final scope 1 NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE 1 Guideline title Social anxiety disorder: recognition, assessment and treatment of social anxiety disorder 1.1 Short title Social anxiety disorder 2 The remit The Department of Health has asked NICE: ‘", "score": 0.75809944 }, { "number": 18, "title": "SOCIAL ANXIETY DISORDER - Social Anxiety Disorder - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK327674", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Social anxiety disorder (previously termed ‘social phobia’) was formally recognised as a separate phobic disorder in the mid-1960s (Marks & Gelder, 1965). The term ‘social anxiety disorder’ reflects current understanding, including in diagnostic manuals, and is used throughout the guideline. As set ", "score": 0.70823324 }, { "number": 19, "title": "Social anxiety disorder: recognition, assessment and ...", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/n/nicecg159guid/pdf", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Page 3 of 33 This guideline partially replaces TA97 and CG123. This guideline is the basis of QS53. Overview This guideline covers recognising, assessing and treating social anxiety disorder (also known as 'social phobia') in children and young people (from school age to 17 years) and adults (aged 1", "score": 0.6884899 }, { "number": 20, "title": "SCOPE FOR THE DEVELOPMENT OF THE CLINICAL GUIDELINE - Social Anxiety Disorder - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK327659", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "National Collaborating Centre for Mental Health (UK). Social Anxiety Disorder: Recognition, Assessment and Treatment. Leicester (UK): British Psychological Society (UK); 2013. (NICE Clinical Guidelines, No. 159.)\n\nCover of Social Anxiety Disorder\n\n## Social Anxiety Disorder: Recognition, Assessment ", "score": 0.6549173 }, { "number": 21, "title": "Clinical practice guideline for social anxiety disorder (2021) - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10496046", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "REFERENCES FOR CQ21 National Institute for Health and Care Excellence (NICE) . Social Anxiety Disorder: Recognition, Assessment and Treatment (Clinical Guideline [CG159]). Leicester: British Psychological Society; 2013. Available from: 318690482 National Institute for Health and Care Excellence (NI", "score": 0.64478505 }, { "number": 22, "title": "SUMMARY OF RECOMMENDATIONS - Social Anxiety Disorder - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK327653", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "a diagnostic or problem identification tool as recommended in recommendation 1.3.2.3 in Common Mental Health Disorders (NICE clinical guideline 12337\n a validated measure for social anxiety, for example, the Social Phobia Inventory (SPIN) or the Liebowitz Social Anxiety Scale (LSAS).\n\n9.2.2.5.\n:", "score": 0.55449516 }, { "number": 23, "title": "Understanding Social Anxiety Disorder in Adolescents and Improving Treatment Outcomes: Applying the Cognitive Model of Clark and Wells (1995) - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6447508", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Cognitive therapy is based on the cognitive model of social anxiety proposed by Clark and Wells (in: Heimberg, Leibowitz, Hope, Scheiber (eds) Social phobia: diagnosis, assessment and treatment, The Guilford Press, New York, 1995). The present review examines the potential application of this adult ", "score": 0.54594 }, { "number": 24, "title": "A clinician's quick guide of evidence-based approaches: Childhood anxiety disorders", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4467238", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "## and post-traumatic stress disorder (PTSD) \n\n2. The National Institute of Clinical Excellence (NICE) published a number of clinical guidelines but not specifically for anxiety disorders in children. There are guidelines for the treatment of OCD, PTSD, and social phobia that include information", "score": 0.5433243 } ], "publishedAt": "2026-09-15T17:25:53.870229+00:00", "updatedAt": "2026-09-15T17:25:53.870229+00:00", "readingMinutes": 6, "slug": "social-anxiety-disorder" }